Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.50 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.50 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.50 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.50 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.50 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.50 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | PGR | P06401 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24274129 | 0.88 | GRIN2D (0.51) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1397747 | 0.88 | GRIN2D (0.48) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL19173347 | 0.88 | GRIN2D (0.51) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL24274119 | 0.85 | GRIN2D (0.44) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1397809 | 0.83 | NPC1 (0.61) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL24138697 | 0.82 | GRIN2D (0.51) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL24274110 | 0.82 | GRIN2D (0.51) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL19173826 | 0.80 | HSD11B1 (0.53) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL19173653 | 0.80 | LMNA (0.46) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL24273772 | 0.79 | GRIN2D (0.44) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12240857-B2 | Adamantane derivatives for the treatment of filovirus infection | ARISAN THERAPEUTICS INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-2683698-B1 | BENZYL-OXATHIAZINE DERIVATES SUBSTITUTED WITH ADAMANTANE OR NORADAMANTANE, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI SA (FR) | 2017-10-04 | — | — | EP | disclosed |
| WO-2017127306-A1 | ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION | ARISAN THERAPEUTICS (US) | 2017-07-27 | — | — | WO | disclosed |
| EP-2683702-B1 | NEW SUBSTITUTED PHENYL OXATHIAZINE DERIVATIVES, METHOD FOR THEIR MANUFACTURE, MEDICINES CONTAINING THESE COMPOUNDS AND THEIR APPLICATION | SANOFI SA (FR) | 2014-12-24 | — | — | EP | disclosed |
| US-8809325-B2 | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof | SANOFI (FR) | 2014-08-19 | — | — | US | disclosed |
| US-8809324-B2 | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof | SANOFI (FR) | 2014-08-19 | — | — | US | disclosed |
| US-8809325-B2 | Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof | SANOFI (FR) | 2014-08-19 | — | — | US | disclosed |
| WO-2012120051-A1 | BENZYL-OXATHIAZINE DERIVATES SUBSTITUTED WITH ADAMANTANE OR NORADAMANTANE, MEDICAMENTS CONTAINING SAID COMPOUNDS AND USE THEREOF | SANOFI (FR) | 2012-09-13 | — | — | WO | disclosed |
| WO-2012120050-A1 | NOVEL SUBSTITUTED PHENYL-OXATHIAZINE DERIVATIVES, METHOD FOR PRODUCING THEM, DRUGS CONTAINING SAID COMPOUNDS AND THE USE THEREOF | SANOFI (FR) | 2012-09-13 | — | — | WO | disclosed |
| US-7985759-B2 | Dipeptidyl peptidase IV inhibitors and processes for their preparation and pharmaceutical compositions containing them | MATRIX LABORATORIES LTD. (IN) | 2011-07-26 | — | — | US | disclosed |
| US-20100160302-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS AND PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | MYLAN LABORATORIES LIMITED (IN) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240857-B2 | Adamantane derivatives for the treatment of filovirus infection | IFNAR1, MEP1B, MEP1A | GRIN2D 3988/4885GRIN3B 2211/4885GRIN1 1774/4885 |
| US-20100160302-A1 | NOVEL DIPEPTIDYL PEPTIDASE IV INHIBITORS AND PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DPP4, DPP3, DPP7 | GRIN2D 2976/4885GRIN3B 1940/4885GRIN1 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.